The STEP program evaluated semaglutide for weight management across distinct populations non-diabetic obesity, type 2 diabetes with obesity, and regimens pairing the drug with intensive behavioral therapy and showed a consistent pattern of clinically meaningful weight loss, with patients who have diabetes generally losing somewhat less than those without
Int J Biol Macromolecules (2024) 275:133742
It is still in the Canadian CSP register, scheduled to take effect in March 2026 and last until March 2028
Thats a more aggressive ceiling that not everyone needs
Contact-sport athletes (MMA, BJJ, rugby, hockey) lean on the BPC/TB-500 combo for repeated soft-tissue impact and GHK-Cu for skin and barrier repair
No Artificial Additives Free from fillers, GMOs, and unnecessary chemicals